Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics


Amneal Pharmaceuticals, Inc. (AMRX)

Today's Latest Price: $3.85 USD

0.06 (1.58%)

Updated Feb 28 6:30pm

Add AMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AMRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for AMRX is 7.92 -- better than 95.44% of US stocks.
  • Amneal Pharmaceuticals Inc's stock had its IPO on March 27, 2018, making it an older stock than just 4.15% of US equities in our set.
  • AMRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 93.33% of US stocks.
  • Stocks that are quantitatively similar to AMRX, based on their financial statements, market capitalization, and price volatility, are GOGO, AUMN, AEHR, BSQR, and THRM.
  • AMRX's SEC filings can be seen here. And to visit Amneal Pharmaceuticals Inc's official web site, go to www.amneal.com.
AMRX Daily Price Range
AMRX 52-Week Price Range

AMRX Stock Price Chart More Charts


AMRX Price/Volume Stats

Current price $3.85 52-week high $14.79
Prev. close $3.79 52-week low $2.27
Day low $3.43 Volume 1,889,900
Day high $3.86 Avg. volume 1,443,743
50-day MA $4.74 Dividend yield N/A
200-day MA $4.40 Market Cap 1.15B

Amneal Pharmaceuticals, Inc. (AMRX) Company Bio


Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.

AMRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.85$1135.39 29391%

We started the process of determining a valid price forecast for Amneal Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amneal Pharmaceuticals Inc ranked in the 99th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 29535.17%; returns of such proportions should be viewed with some skepticism, though. As for the metrics that stood out in our discounted cash flow analysis of Amneal Pharmaceuticals Inc, consider:

  • 15% of the company's capital comes from equity, which is greater than only 3.92% of stocks in our cash flow based forecasting set.
  • Amneal Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 64 -- greater than 96.63% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), Amneal Pharmaceuticals Inc has a reliance on debt greater than 96.88% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%28812%
1%29101%
2%29391%
3%29680%
4%29969%
5%30258%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMRX, try RHE, VRTX, BEAT, ASRT, and RDY.


AMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

AMRX Latest Social Stream


Loading social stream, please wait...

View Full AMRX Social Stream

AMRX Price Returns

1-mo -17.03%
3-mo 2.39%
6-mo 50.98%
1-year -71.48%
3-year -58.60%
5-year -90.48%
YTD -20.12%
2019 -64.38%
2018 -18.74%
2017 25.66%
2016 -69.01%
2015 34.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6065 seconds.